[go: up one dir, main page]

MX2017000855A - Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares. - Google Patents

Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.

Info

Publication number
MX2017000855A
MX2017000855A MX2017000855A MX2017000855A MX2017000855A MX 2017000855 A MX2017000855 A MX 2017000855A MX 2017000855 A MX2017000855 A MX 2017000855A MX 2017000855 A MX2017000855 A MX 2017000855A MX 2017000855 A MX2017000855 A MX 2017000855A
Authority
MX
Mexico
Prior art keywords
cyclosporin
subconjunctival
suspension
suspension compositions
periocular injection
Prior art date
Application number
MX2017000855A
Other languages
English (en)
Other versions
MX384947B (es
Inventor
V Gore Anuradha
P Pujara Chetan
Neervannan Sesha
Wu Ke
Hou Hao
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2017000855A publication Critical patent/MX2017000855A/es
Publication of MX384947B publication Critical patent/MX384947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación hace referencia a formulaciones en suspensión y a sistemas para el tratamiento de afecciones oculares. Las formulaciones en suspensión pueden incluir ciclosporina A y, en algunas modalidades, Forma 1 o Forma 2 de ciclosporina A. Se puede proveer un sistema de administración que incluye dos partes: una primera parte que contiene partículas de ciclosporina y una segunda parte que contiene otros componentes que se pueden combinar con la primera parte para producir una formulación en suspensión. Es posible inyectar la suspensión en el espacio subconjuntival u otro espacio periocular para tratar afecciones oculares, tales como ojos secos.
MX2017000855A 2014-07-18 2015-07-20 Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares. MX384947B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026200P 2014-07-18 2014-07-18
PCT/US2015/041166 WO2016011449A1 (en) 2014-07-18 2015-07-20 Suspension compositions of cyclosporin a for subconjunctival and periocular injection

Publications (2)

Publication Number Publication Date
MX2017000855A true MX2017000855A (es) 2017-05-01
MX384947B MX384947B (es) 2025-03-14

Family

ID=53762390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000855A MX384947B (es) 2014-07-18 2015-07-20 Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.

Country Status (14)

Country Link
US (1) US10780048B2 (es)
EP (1) EP3169308B1 (es)
KR (1) KR20170030093A (es)
AU (1) AU2015289387B2 (es)
BR (1) BR112017001017A2 (es)
CA (1) CA2955037A1 (es)
CL (1) CL2017000120A1 (es)
CO (1) CO2017001454A2 (es)
MX (1) MX384947B (es)
MY (1) MY196111A (es)
PH (1) PH12017500098A1 (es)
RU (1) RU2713953C2 (es)
SA (1) SA517380738B1 (es)
WO (1) WO2016011449A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
CN110114119B (zh) * 2016-10-12 2022-05-31 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN112315901B (zh) * 2019-07-17 2022-10-25 四川弘合生物科技有限公司 一种注射用浓溶液及其制备方法
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11523987B2 (en) 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
US11510930B2 (en) 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252319A (en) 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
CN1638734A (zh) 2002-02-22 2005-07-13 参天制药株式会社 微粒结膜下给药的药物释放系统
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US8288348B2 (en) * 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
BRPI0709872A2 (pt) * 2006-04-03 2011-07-26 Teva Pharma micropartÍculas de drogas
US20080146497A1 (en) 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
EP3521302A1 (en) 2011-05-27 2019-08-07 Allergan, Inc. A new crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
EP2780358B1 (en) 2011-11-15 2016-03-23 Allergan, Inc. Cyclosporine a form 2 and method of making same
DK2779994T3 (da) * 2011-11-15 2020-05-18 Allergan Inc Suspensioner af cyclosporin a form 2
KR102015151B1 (ko) * 2011-11-15 2019-08-27 알러간, 인코포레이티드 사이클로스포린 a 제2형의 고압멸균처리 가능한 현탁액
EP3381443A1 (en) 2011-11-15 2018-10-03 Allergan, Inc. Sustained action formulation of cyclosporin form 2

Also Published As

Publication number Publication date
RU2713953C2 (ru) 2020-02-11
WO2016011449A1 (en) 2016-01-21
US10780048B2 (en) 2020-09-22
CA2955037A1 (en) 2016-01-21
MX384947B (es) 2025-03-14
MY196111A (en) 2023-03-15
SA517380738B1 (ar) 2021-04-11
AU2015289387A1 (en) 2017-02-23
RU2017103632A (ru) 2018-08-20
RU2017103632A3 (es) 2019-02-01
AU2015289387B2 (en) 2020-10-22
EP3169308B1 (en) 2021-01-27
KR20170030093A (ko) 2017-03-16
US20160015632A1 (en) 2016-01-21
CL2017000120A1 (es) 2017-09-08
EP3169308A1 (en) 2017-05-24
BR112017001017A2 (pt) 2018-01-23
PH12017500098A1 (en) 2017-05-22
CO2017001454A2 (es) 2017-02-28

Similar Documents

Publication Publication Date Title
MX2017000855A (es) Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.
EA201992247A1 (ru) Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
TW201613588A (en) Ophthalmic composition
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX385109B (es) Formulaciones de anticuerpos.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
WO2015013330A3 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
MX2017008189A (es) Composicion farmceutica que comprende plasminogeno y usos de este.
MX2017004828A (es) Composicion oftalmica que comprende ciclosporina y trehalosa.
MX2024010721A (es) Formulaciones topicas que contienen ciclosporina y usos de las mismas.
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX377919B (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
EA201791147A1 (ru) Фармацевтическая композиция, ее получение и применения
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
MX388310B (es) Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares